MANDELAMINE
Dead / Abandoned — Abandoned — no statement of use filed (as of 11 Mar 2024)
What this means for you
This application is over — abandoned 11 Mar 2024. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 97381321
- Mark type
- Stylized text
- Filed
- 26 Apr 2022
- Published for opposition
- 14 Jun 2022
- Abandoned
- 11 Mar 2024
- Attorney of record
- Daniel G Worley Jr.
Goods and services
- Class 005 — Pharmaceuticals: Antibacterial pharmaceuticals; Urinary tract disinfectants; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for use in urology
Owner
- Edenbridge Pharmaceuticals, LLC, Parsippany, NJ, US
- Edenbridge Pharmaceuticals, LLC, Parsippany, NJ, US
Prosecution history
- 11 Mar 2024 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 11 Mar 2024 — ABANDONMENT - NO USE STATEMENT FILED
- 09 Aug 2023 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 07 Aug 2023 — SOU EXTENSION 2 GRANTED
- 07 Aug 2023 — SOU EXTENSION 2 FILED
- 07 Aug 2023 — SOU TEAS EXTENSION RECEIVED
- 10 Feb 2023 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 08 Feb 2023 — SOU EXTENSION 1 GRANTED
- 08 Feb 2023 — SOU EXTENSION 1 FILED
- 08 Feb 2023 — SOU TEAS EXTENSION RECEIVED
- 09 Aug 2022 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 14 Jun 2022 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 14 Jun 2022 — PUBLISHED FOR OPPOSITION
- 25 May 2022 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 12 May 2022 — APPROVED FOR PUB - PRINCIPAL REGISTER